Use risk-based approach to monitor trials, US FDA recommends
This article was originally published in Clinica
The US FDA has issued final guidance on how medical device should oversee their clinical investigations that advocates adopting a risk-based approach to monitoring.
You may also be interested in...
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Novartis's Adakveo for preventing recurrent vaso-occlusive crises in patients with sickle cell disease. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).